Navigation Links
Abbott vs. Thailand has implications for innovation and access

Many of you have been following the Abbott Laboratories story regarding its Kaletra AIDS drug and the conflict with the government of Thailand over patent protection and drug pricing. Some of you may regard this as a relatively isolated tiff between a single drug company and another developing country. Others consider this to be a ......

Full article >>> iland, remarking that Abbott has spent over $300 million last year alone in humanitarian relief worldwide. Activists as well as shareholders supportive of the Abbott decision spar (fortunately peaceably).

Without taking sides, this sounds to me like a lose-lose situation out of a Shakespearean "tragicomedy," layered by miscommunication and blinkered outlooks. Both sides have valid points,......

Full article >>> ieved a short-term victory on Aluvia pricing, but it lost out on significant other life-saving medicines for their population. That being said, AIDS is a monumental problem in Thailand. The prevalence in that population is estimated at over one percent, which consequently makes AIDS one of the leading causes of death in that country. To a large exten......

Full article >>> s are exporting medicines to developing countries. That reason is called comparative advantage. The U.S. has a comparative advantage relative to other nations in quite a few industries. Aircraft is one of them, military technology is another, financial services also ranks high on the list and, of course, pharmaceuticals and medical technology are significant sources of comparative advantage.
......

Full article >>> t opportunity at medical diplomacy and a failed chance at improving the perception of the U.S. among other nations.

The efforts of U.S. companies to export healthcare technology and medical expertise to other nations becomes not just a business matter but something that should be part of our foreign policy and all the support and encouragement that entails.

So how does this broad......

Full article >>> usly speaking about the Civil War and arguing not only for his vision of a united United States but perhaps more importantly pointing out the state of mind required to achieve that vision. In our time, the dogma that innovation justifies high prices is not necessarily invalid, but we need to think anew and act anew.

Previous articles by Ogan Gurel



Source:wistechnology.com By Ogan Gurel 05/01/07


Related biology technology :

1. A prognosis for GE and Abbott Diagnostics
2. Wisconsin court halts Abbotts sale of genotyping products
3. Wisconsin court affirms damages in Innogenetics, Abbott patent case
4. Abbott Labs campus in Kenosha could send ripples through local biotech
5. Abbott Executive Jim Tyree Takes IBIO Helm
6. Promega Announces Agreement with Abbott
7. Changes to U.S. patent law must nurture our culture of innovation
8. Visions: Benson touts embedded innovation
9. UW System must remove barriers to innovation
10. In western Wisconsin, the innovation economy is growing
11. Scott Converse, UW-Madison School of Business, on the innovation mind-set
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... 2017  BioGenex, a global leader in molecular ... novel system for quantitative immunohistochemistry (IHC). The system ... Rochester (NY, USA) and Konica-Minolta Inc. ( ... able to accurately quantify the expression of an ... factor receptor-2) in clinical samples. Quantitative IHC is ...
(Date:2/17/2017)... , Feb. 17, 2017  Protagonist Therapeutics, ... data on its oral peptide drug candidates, PTG-100 ... of the European Crohn,s and Colitis Organization (ECCO).  ... Barcelona, Spain from February 15 ... detail preclinical data on Protagonist drug candidates PTG-100 ...
(Date:2/16/2017)...  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing ... treatment for triple negative breast cancer (TNBC), announced today their ... program. The YEi Start in ... entrepreneurs grow their business in France ... selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... , Feb. 16, 2017  ArmaGen, Inc., a ... therapies to treat severe neurological disorders, today reported ... with AGT-181, the company,s investigational therapy for the ... as mucopolysaccharidosis type I, or MPS I). The ... (POC) study, presented today at the 13 th ...
Breaking Biology Technology:
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):